1 Market Overview of CAR-T Therapy in Haematological Malignancy 1.1 CAR-T Therapy in Haematological Malignancy Market Overview 1.1.1 CAR-T Therapy in Haematological Malignancy Product Scope 1.1.2 CAR-T Therapy in Haematological Malignancy Market Status and Outlook 1.2 Global CAR-T Therapy in Haematological Malignancy Market Size Overview by Region 2016 VS 2021VS 2027 1.3 Global CAR-T Therapy in Haematological Malignancy Market Size by Region (2016-2027) 1.4 Global CAR-T Therapy in Haematological Malignancy Historic Market Size by Region (2016-2021) 1.5 Global CAR-T Therapy in Haematological Malignancy Market Size Forecast by Region (2022-2027) 1.6 Key Regions, CAR-T Therapy in Haematological Malignancy Market Size (2016-2027) 1.6.1 North America CAR-T Therapy in Haematological Malignancy Market Size (2016-2027) 1.6.2 Europe CAR-T Therapy in Haematological Malignancy Market Size (2016-2027) 1.6.3 Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size (2016-2027) 1.6.4 Latin America CAR-T Therapy in Haematological Malignancy Market Size (2016-2027) 1.6.5 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size (2016-2027) 2 CAR-T Therapy in Haematological Malignancy Market Overview by Type 2.1 Global CAR-T Therapy in Haematological Malignancy Market Size by Type: 2016 VS 2021 VS 2027 2.2 Global CAR-T Therapy in Haematological Malignancy Historic Market Size by Type (2016-2021) 2.3 Global CAR-T Therapy in Haematological Malignancy Forecasted Market Size by Type (2022-2027) 2.4 Allogeneic 2.5 Autologous 3 CAR-T Therapy in Haematological Malignancy Market Overview by Application 3.1 Global CAR-T Therapy in Haematological Malignancy Market Size by Application: 2016 VS 2021 VS 2027 3.2 Global CAR-T Therapy in Haematological Malignancy Historic Market Size by Application (2016-2021) 3.3 Global CAR-T Therapy in Haematological Malignancy Forecasted Market Size by Application (2022-2027) 3.4 Hospitals 3.5 Cancer Research Centers 3.6 Others 4 CAR-T Therapy in Haematological Malignancy Competition Analysis by Players 4.1 Global CAR-T Therapy in Haematological Malignancy Market Size by Players (2016-2021) 4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in CAR-T Therapy in Haematological Malignancy as of 2020) 4.3 Date of Key Players Enter into CAR-T Therapy in Haematological Malignancy Market 4.4 Global Top Players CAR-T Therapy in Haematological Malignancy Headquarters and Area Served 4.5 Key Players CAR-T Therapy in Haematological Malignancy Product Solution and Service 4.6 Competitive Status 4.6.1 CAR-T Therapy in Haematological Malignancy Market Concentration Rate 4.6.2 Mergers & Acquisitions, Expansion Plans 5 Company (Top Players) Profiles and Key Data 5.1 Celgene (Juno Therapeutics) 5.1.1 Celgene (Juno Therapeutics) Profile 5.1.2 Celgene (Juno Therapeutics) Main Business 5.1.3 Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Products, Services and Solutions 5.1.4 Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Revenue (US$ Million) & (2016-2021) 5.1.5 Celgene (Juno Therapeutics) Recent Developments 5.2 Novartis 5.2.1 Novartis Profile 5.2.2 Novartis Main Business 5.2.3 Novartis CAR-T Therapy in Haematological Malignancy Products, Services and Solutions 5.2.4 Novartis CAR-T Therapy in Haematological Malignancy Revenue (US$ Million) & (2016-2021) 5.2.5 Novartis Recent Developments 5.3 Gilead (Kite Pharma) 5.5.1 Gilead (Kite Pharma) Profile 5.3.2 Gilead (Kite Pharma) Main Business 5.3.3 Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Products, Services and Solutions 5.3.4 Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Revenue (US$ Million) & (2016-2021) 5.3.5 Pfizer Recent Developments 5.4 Pfizer 5.4.1 Pfizer Profile 5.4.2 Pfizer Main Business 5.4.3 Pfizer CAR-T Therapy in Haematological Malignancy Products, Services and Solutions 5.4.4 Pfizer CAR-T Therapy in Haematological Malignancy Revenue (US$ Million) & (2016-2021) 5.4.5 Pfizer Recent Developments 5.5 CARsgen Therapeutics 5.5.1 CARsgen Therapeutics Profile 5.5.2 CARsgen Therapeutics Main Business 5.5.3 CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Products, Services and Solutions 5.5.4 CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Revenue (US$ Million) & (2016-2021) 5.5.5 CARsgen Therapeutics Recent Developments 5.6 Autolus Therapeutics 5.6.1 Autolus Therapeutics Profile 5.6.2 Autolus Therapeutics Main Business 5.6.3 Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Products, Services and Solutions 5.6.4 Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Revenue (US$ Million) & (2016-2021) 5.6.5 Autolus Therapeutics Recent Developments 5.7 Aurora BioPharma 5.7.1 Aurora BioPharma Profile 5.7.2 Aurora BioPharma Main Business 5.7.3 Aurora BioPharma CAR-T Therapy in Haematological Malignancy Products, Services and Solutions 5.7.4 Aurora BioPharma CAR-T Therapy in Haematological Malignancy Revenue (US$ Million) & (2016-2021) 5.7.5 Aurora BioPharma Recent Developments 5.8 Sorrento Therapeutics 5.8.1 Sorrento Therapeutics Profile 5.8.2 Sorrento Therapeutics Main Business 5.8.3 Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Products, Services and Solutions 5.8.4 Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Revenue (US$ Million) & (2016-2021) 5.8.5 Sorrento Therapeutics Recent Developments 5.9 Mustang Bio 5.9.1 Mustang Bio Profile 5.9.2 Mustang Bio Main Business 5.9.3 Mustang Bio CAR-T Therapy in Haematological Malignancy Products, Services and Solutions 5.9.4 Mustang Bio CAR-T Therapy in Haematological Malignancy Revenue (US$ Million) & (2016-2021) 5.9.5 Mustang Bio Recent Developments 5.10 Bluebird Bio 5.10.1 Bluebird Bio Profile 5.10.2 Bluebird Bio Main Business 5.10.3 Bluebird Bio CAR-T Therapy in Haematological Malignancy Products, Services and Solutions 5.10.4 Bluebird Bio CAR-T Therapy in Haematological Malignancy Revenue (US$ Million) & (2016-2021) 5.10.5 Bluebird Bio Recent Developments 5.11 Collectis 5.11.1 Collectis Profile 5.11.2 Collectis Main Business 5.11.3 Collectis CAR-T Therapy in Haematological Malignancy Products, Services and Solutions 5.11.4 Collectis CAR-T Therapy in Haematological Malignancy Revenue (US$ Million) & (2016-2021) 5.11.5 Collectis Recent Developments 5.12 Allogene Therapeutics 5.12.1 Allogene Therapeutics Profile 5.12.2 Allogene Therapeutics Main Business 5.12.3 Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Products, Services and Solutions 5.12.4 Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Revenue (US$ Million) & (2016-2021) 5.12.5 Allogene Therapeutics Recent Developments 5.13 Celyad 5.13.1 Celyad Profile 5.13.2 Celyad Main Business 5.13.3 Celyad CAR-T Therapy in Haematological Malignancy Products, Services and Solutions 5.13.4 Celyad CAR-T Therapy in Haematological Malignancy Revenue (US$ Million) & (2016-2021) 5.13.5 Celyad Recent Developments 6 North America 6.1 North America CAR-T Therapy in Haematological Malignancy Market Size by Country (2016-2027) 6.2 United States 6.3 Canada 7 Europe 7.1 Europe CAR-T Therapy in Haematological Malignancy Market Size by Country (2016-2027) 7.2 Germany 7.3 France 7.4 U.K. 7.5 Italy 7.6 Russia 7.7 Nordic 7.8 Rest of Europe 8 Asia-Pacific 8.1 Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size by Region (2016-2027) 8.2 China 8.3 Japan 8.4 South Korea 8.5 Southeast Asia 8.6 India 8.7 Australia 8.8 Rest of Asia-Pacific 9 Latin America 9.1 Latin America CAR-T Therapy in Haematological Malignancy Market Size by Country (2016-2027) 9.2 Mexico 9.3 Brazil 9.4 Rest of Latin America 10 Middle East & Africa 10.1 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Country (2016-2027) 10.2 Turkey 10.3 Saudi Arabia 10.4 UAE 10.5 Rest of Middle East & Africa 11 CAR-T Therapy in Haematological Malignancy Market Dynamics 11.1 CAR-T Therapy in Haematological Malignancy Industry Trends 11.2 CAR-T Therapy in Haematological Malignancy Market Drivers 11.3 CAR-T Therapy in Haematological Malignancy Market Challenges 11.4 CAR-T Therapy in Haematological Malignancy Market Restraints 12 Research Finding /Conclusion 13 Methodology and Data Source 13.1 Methodology/Research Approach 13.1.1 Research Programs/Design 13.1.2 Market Size Estimation 13.1.3 Market Breakdown and Data Triangulation 13.2 Data Source 13.2.1 Secondary Sources 13.2.2 Primary Sources 13.3 Disclaimer 13.4 Author List

List of Tables Table 1. Global Market CAR-T Therapy in Haematological Malignancy Market Size (US$ Million) Comparison by Region 2016 VS 2021 VS 2027 Table 2. Global CAR-T Therapy in Haematological Malignancy Market Size by Region (2016-2021) & (US$ Million) Table 3. Global CAR-T Therapy in Haematological Malignancy Market Size Share by Region (2016-2021) Table 4. Global CAR-T Therapy in Haematological Malignancy Forecasted Market Size by Region (2022-2027) & (US$ Million) Table 5. Global CAR-T Therapy in Haematological Malignancy Forecasted Market Size Share by Region (2022-2027) Table 6. Global CAR-T Therapy in Haematological Malignancy Market Size (US$ Million) by Type: 2016 VS 2021 VS 2027 Table 7. Global CAR-T Therapy in Haematological Malignancy Market Size by Type (2016-2021) & (US$ Million) Table 8. Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Type (2016-2021) Table 9. Global CAR-T Therapy in Haematological Malignancy Forecasted Market Size by Type (2022-2027) & (US$ Million) Table 10. Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Type (2022-2027) Table 11. Global CAR-T Therapy in Haematological Malignancy Market Size (US$ Million) by Application: 2016 VS 2021 VS 2027 Table 12. Global CAR-T Therapy in Haematological Malignancy Market Size by Application (2016-2021) & (US$ Million) Table 13. Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Application (2016-2021) Table 14. Global CAR-T Therapy in Haematological Malignancy Forecasted Market Size by Application (2022-2027) & (US$ Million) Table 15. Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Application (2022-2027) Table 16. Global CAR-T Therapy in Haematological Malignancy Revenue (US$ Million) by Players (2016-2021) Table 17. Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Players (2016-2021) Table 18. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in CAR-T Therapy in Haematological Malignancy as of 2020) Table 19. Date of Key Manufacturers Enter into CAR-T Therapy in Haematological Malignancy Market Table 20. Global CAR-T Therapy in Haematological Malignancy Top Players Headquarters and Area Served Table 21. CAR-T Therapy in Haematological Malignancy Product Solution and Service Table 22. Global CAR-T Therapy in Haematological Malignancy Players Market Concentration Ratio (CR5 and HHI) Table 23. Mergers & Acquisitions, Expansion Plans Table 24. Celgene (Juno Therapeutics) Basic Information List Table 25. Celgene (Juno Therapeutics) Description and Business Overview Table 26. Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Products, Services and Solutions Table 27. Revenue (US$ Million) in CAR-T Therapy in Haematological Malignancy Business of Celgene (Juno Therapeutics) (2016-2021) Table 28. Celgene (Juno Therapeutics) Recent Developments Table 29. Novartis Basic Information List Table 30. Novartis Description and Business Overview Table 31. Novartis CAR-T Therapy in Haematological Malignancy Products, Services and Solutions Table 32. Revenue (US$ Million) in CAR-T Therapy in Haematological Malignancy Business of Novartis (2016-2021) Table 33. Novartis Recent Developments Table 34. Gilead (Kite Pharma) Basic Information List Table 35. Gilead (Kite Pharma) Description and Business Overview Table 36. Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Products, Services and Solutions Table 37. Revenue (US$ Million) in CAR-T Therapy in Haematological Malignancy Business of Gilead (Kite Pharma) (2016-2021) Table 38. Gilead (Kite Pharma) Recent Developments Table 39. Pfizer Basic Information List Table 40. Pfizer Description and Business Overview Table 41. Pfizer CAR-T Therapy in Haematological Malignancy Products, Services and Solutions Table 42. Revenue (US$ Million) in CAR-T Therapy in Haematological Malignancy Business of Pfizer (2016-2021) Table 43. Pfizer Recent Developments Table 44. CARsgen Therapeutics Basic Information List Table 45. CARsgen Therapeutics Description and Business Overview Table 46. CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Products, Services and Solutions Table 47. Revenue (US$ Million) in CAR-T Therapy in Haematological Malignancy Business of CARsgen Therapeutics (2016-2021) Table 48. CARsgen Therapeutics Recent Developments Table 49. Autolus Therapeutics Basic Information List Table 50. Autolus Therapeutics Description and Business Overview Table 51. Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Products, Services and Solutions Table 52. Revenue (US$ Million) in CAR-T Therapy in Haematological Malignancy Business of Autolus Therapeutics (2016-2021) Table 53. Autolus Therapeutics Recent Developments Table 54. Aurora BioPharma Basic Information List Table 55. Aurora BioPharma Description and Business Overview Table 56. Aurora BioPharma CAR-T Therapy in Haematological Malignancy Products, Services and Solutions Table 57. Revenue (US$ Million) in CAR-T Therapy in Haematological Malignancy Business of Aurora BioPharma (2016-2021) Table 58. Aurora BioPharma Recent Developments Table 59. Sorrento Therapeutics Basic Information List Table 60. Sorrento Therapeutics Description and Business Overview Table 61. Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Products, Services and Solutions Table 62. Revenue (US$ Million) in CAR-T Therapy in Haematological Malignancy Business of Sorrento Therapeutics (2016-2021) Table 63. Sorrento Therapeutics Recent Developments Table 64. Mustang Bio Basic Information List Table 65. Mustang Bio Description and Business Overview Table 66. Mustang Bio CAR-T Therapy in Haematological Malignancy Products, Services and Solutions Table 67. Revenue (US$ Million) in CAR-T Therapy in Haematological Malignancy Business of Mustang Bio (2016-2021) Table 68. Mustang Bio Recent Developments Table 69. Bluebird Bio Basic Information List Table 70. Bluebird Bio Description and Business Overview Table 71. Bluebird Bio CAR-T Therapy in Haematological Malignancy Products, Services and Solutions Table 72. Revenue (US$ Million) in CAR-T Therapy in Haematological Malignancy Business of Bluebird Bio (2016-2021) Table 73. Bluebird Bio Recent Developments Table 74. Collectis Basic Information List Table 75. Collectis Description and Business Overview Table 76. Collectis CAR-T Therapy in Haematological Malignancy Products, Services and Solutions Table 77. Revenue (US$ Million) in CAR-T Therapy in Haematological Malignancy Business of Collectis (2016-2021) Table 78. Collectis Recent Developments Table 79. Allogene Therapeutics Basic Information List Table 80. Allogene Therapeutics Description and Business Overview Table 81. Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Products, Services and Solutions Table 82. Revenue (US$ Million) in CAR-T Therapy in Haematological Malignancy Business of Allogene Therapeutics (2016-2021) Table 83. Allogene Therapeutics Recent Developments Table 84. Celyad Basic Information List Table 85. Celyad Description and Business Overview Table 86. Celyad CAR-T Therapy in Haematological Malignancy Products, Services and Solutions Table 87. Revenue (US$ Million) in CAR-T Therapy in Haematological Malignancy Business of Celyad (2016-2021) Table 88. Celyad Recent Developments Table 89. North America CAR-T Therapy in Haematological Malignancy Market Size by Country (2016-2021) & (US$ Million) Table 90. North America CAR-T Therapy in Haematological Malignancy Market Size by Country (2022-2027) & (US$ Million) Table 91. Europe CAR-T Therapy in Haematological Malignancy Market Size by Country (2016-2021) & (US$ Million) Table 92. Europe CAR-T Therapy in Haematological Malignancy Market Size by Country (2022-2027) & (US$ Million) Table 93. Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size by Region (2016-2021) & (US$ Million) Table 94. Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size by Region (2022-2027) & (US$ Million) Table 95. Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Share by Region (2016-2021) Table 96. Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Share by Region (2022-2027) Table 97. Latin America CAR-T Therapy in Haematological Malignancy Market Size by Country (2016-2021) & (US$ Million) Table 98. Latin America CAR-T Therapy in Haematological Malignancy Market Size by Country (2022-2027) & (US$ Million) Table 99. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Players (2016-2021) & (US$ Million) Table 100. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Country (2022-2027) & (US$ Million) Table 101. CAR-T Therapy in Haematological Malignancy Market Trends Table 102. CAR-T Therapy in Haematological Malignancy Market Drivers Table 103. CAR-T Therapy in Haematological Malignancy Market Challenges Table 104. CAR-T Therapy in Haematological Malignancy Market Restraints Table 105. Research Programs/Design for This Report Table 106. Key Data Information from Secondary Sources Table 107. Key Data Information from Primary Sources List of Figures Figure 1. Global CAR-T Therapy in Haematological Malignancy Market Size Year-over-Year 2016-2027 & (US$ Million) Figure 2. Global CAR-T Therapy in Haematological Malignancy Market Size (US$ Million), 2016 VS 2021 VS 2027 Figure 3. Global CAR-T Therapy in Haematological Malignancy Market Share by Regions: 2021 VS 2027 Figure 4. Global CAR-T Therapy in Haematological Malignancy Forecasted Market Size Share by Region (2022-2027) Figure 5. North America CAR-T Therapy in Haematological Malignancy Market Size (US$ Million) Growth Rate (2016-2027) Figure 6. Europe CAR-T Therapy in Haematological Malignancy Market Size (US$ Million) and Growth Rate (2016-2027) Figure 7. Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size (US$ Million) and Growth Rate (2016-2027) Figure 8. Latin America CAR-T Therapy in Haematological Malignancy Market Size (US$ Million) and Growth Rate (2016-2027) Figure 9. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size (US$ Million) and Growth Rate (2016-2027) Figure 10. Global CAR-T Therapy in Haematological Malignancy Market Size Share by Type in 2021 & 2027 Figure 11. Allogeneic Market Size (US$ Million) YoY Growth (2016-2027) Figure 12. Autologous Market Size (US$ Million) YoY Growth (2016-2027) Figure 13. Global CAR-T Therapy in Haematological Malignancy Market Size Share by Application in 2021 & 2027 Figure 14. Hospitals Market Size (US$ Million) YoY Growth (2016-2027) Figure 15. Cancer Research Centers Market Size (US$ Million) YoY Growth (2016-2027) Figure 16. Others Market Size (US$ Million) YoY Growth (2016-2027) Figure 17. CAR-T Therapy in Haematological Malignancy Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2020 Figure 18. Global Top 5 and Top 10 Players CAR-T Therapy in Haematological Malignancy Market Share in 2020 Figure 19. North America CAR-T Therapy in Haematological Malignancy Market Share by Country (2016-2027) Figure 20. United States CAR-T Therapy in Haematological Malignancy Market Size (2016-2027) & (US$ Million) Figure 21. Canada CAR-T Therapy in Haematological Malignancy Market Size (2016-2027) & (US$ Million) Figure 22. Germany CAR-T Therapy in Haematological Malignancy Market Size (2016-2027) & (US$ Million) Figure 23. France CAR-T Therapy in Haematological Malignancy Market Size (2016-2027) & (US$ Million) Figure 24. U.K. CAR-T Therapy in Haematological Malignancy Market Size (2016-2027) & (US$ Million) Figure 25. Italy CAR-T Therapy in Haematological Malignancy Market Size (2016-2027) & (US$ Million) Figure 26. Russia CAR-T Therapy in Haematological Malignancy Market Size (2016-2027) & (US$ Million) Figure 27. Nordic CAR-T Therapy in Haematological Malignancy Market Size (2016-2027) & (US$ Million) Figure 28. Rest of Europe CAR-T Therapy in Haematological Malignancy Market Size (2016-2027) & (US$ Million) Figure 29. Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Share by Region (2016-2027) Figure 30. China CAR-T Therapy in Haematological Malignancy Market Size (2016-2027) & (US$ Million) Figure 31. Japan CAR-T Therapy in Haematological Malignancy Market Size (2016-2027) & (US$ Million) Figure 32. South Korea CAR-T Therapy in Haematological Malignancy Market Size (2016-2027) & (US$ Million) Figure 33. Southeast Asia CAR-T Therapy in Haematological Malignancy Market Size (2016-2027) & (US$ Million) Figure 34. India CAR-T Therapy in Haematological Malignancy Market Size (2016-2027) & (US$ Million) Figure 35. Australia CAR-T Therapy in Haematological Malignancy Market Size (2016-2027) & (US$ Million) Figure 36. Rest of Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size (2016-2027) & (US$ Million) Figure 37. Latin America CAR-T Therapy in Haematological Malignancy Market Share by Country (2016-2027) Figure 38. Mexico CAR-T Therapy in Haematological Malignancy Market Size (2016-2027) & (US$ Million) Figure 39. Brazil CAR-T Therapy in Haematological Malignancy Market Size (2016-2027) & (US$ Million) Figure 40. Rest of Latin America CAR-T Therapy in Haematological Malignancy Market Size (2016-2027) & (US$ Million) Figure 41. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Share by Country (2016-2027) Figure 42. Turkey CAR-T Therapy in Haematological Malignancy Market Size (2016-2027) & (US$ Million) Figure 43. Saudi Arabia CAR-T Therapy in Haematological Malignancy Market Size (2016-2027) & (US$ Million) Figure 44. UAE CAR-T Therapy in Haematological Malignancy Market Size (2016-2027) & (US$ Million) Figure 45. Rest of Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size (2016-2027) & (US$ Million) Figure 46. Bottom-up and Top-down Approaches for This Report Figure 47. Data Triangulation

Celgene (Juno Therapeutics) Novartis Gilead (Kite Pharma) Pfizer CARsgen Therapeutics Autolus Therapeutics Aurora BioPharma Sorrento Therapeutics Mustang Bio Bluebird Bio Collectis Allogene Therapeutics Celyad